DiscoveryBioMed Revenue and Competitors

DiscoveryBioMed, Inc. (DBM) is a life sciences and biotechnology company focused on integrating biologically- and disease-relevant human cell cultures and lines into all relevant steps in the Drug Discovery Critical Path. DBM specializes in multiplexed bioassays of targets and phenotypes using both mono- and multi-culture designs for primary Drug Discovery, as well as, hit-to-lead validation of existing hit-to-lead assets. Complementing its Drug Discovery efforts, DBM also specializes in custom cell culture and engineering and implementation of such cells at any and all inflections points within the Critical Path. It is DBM’s belief that our approach to Drug Discovery and Development serves as a complement to the more traditional approach within the BioPharmaceutical Indstury to improve the viability of hit, validated hit-to-lead and lead clinical candidate drugs.